Pacira BioSciences, Inc. (PCRX)
Nasdaq: PCRX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2007
Grade6.3
◀ Past 8.0● Present 6.1▶ Future 4.9
Who owns Pacira BioSciences, Inc.
As filed with the SECHolders of 5% or more
5
Blackrock, Inc. holds 15.2% of Common Stock, as its SCHEDULE 13G/A filed Apr 28, 2025 says.
Directors and officers
16
report now, of 37 people on the record since 2011. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 28, 2025 · Common Stock
Vanguard Portfolio Management
SCHEDULE 13G · filed May 1, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Vanguard Capital Management
SCHEDULE 13G · filed May 1, 2026 · Common Stock
Dimensional Fund Advisors LP
SCHEDULE 13G · filed Apr 9, 2026 · Common Stock
Renaissance Technologies LLC
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.34% in Aug 13, 2025
Pacer Advisors, Inc.
SCHEDULE 13G/A · filed May 2, 2025 · Common Stock, Par Value $0.001 Per Share · reported falling below 5%, from 6.93% in May 2, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Apr 21, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.1% in Jan 15, 2025
Doma Perpetual Capital Management LLC
SCHEDULE 13D/A · filed Oct 13, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 7.3% in Mar 12, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What PCRX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
GQ Bio Acquisition
A company bought · acquisition · Feb 2025 · owns, named in the 10-K filed Feb 26, 2026
Flexion Acquisition
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
Flexion Therapeutics, Inc.
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
8 subsidiaries in 5 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
17sales
0purchases
16sales on a scheduled plan
5people selling
$2.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 37 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Cross Shawn | Chief Financial Officer | 7 | $1.5M | 7 | 0 | $0 |
| Riker Lauren Bullaro | Senior Vice President, Finance | 4 | $500,000 | 4 | 0 | $0 |
| Williams Kristen Marie | Chief Administrative Officer | 2 | $500,000 | 2 | 0 | $0 |
| Slonin Jonathan | Chief Medical Officer | 3 | $200,000 | 3 | 0 | $0 |
| Froimson Mark | director | 1 | $0 | 0 | 0 | $0 |